Showing results (341-350 of 360) with videos related to

Sort By:
Pageof 36
Diseases (Basel, Switzerland)|May 23, 2023
Primary Cardiac Sarcoma: Clinical Characteristics and Prognostic Factors over the Past 2 DecadesAyrton Bangolo, Pierre Fwelo, Kritika M Iyer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 16, 2013
Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processingXingrong Liu, Harvey Wong, Kimberly Scearce-Levie, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase InhibitorMalcolm P Huestis, Matthew R Durk, Charles Eigenbrot, et al.
Journal of Medicinal Chemistry|October 16, 2012
Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitorsEmily J Hanan, Anne van Abbema, Kathy Barrett, et al.
Journal of Medicinal Chemistry|March 29, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase InhibitorMalcolm P Huestis, Darlene Dela Cruz, Antonio G DiPasquale, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2013
2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitorsMichael Siu, Richard Pastor, Wendy Liu, et al.
Microbiology Spectrum|October 6, 2021
Averting an Outbreak of SARS-CoV-2 in a University Residence Hall through Wastewater SurveillanceRyland Corchis-Scott, Qiudi Geng, Rajesh Seth, et al.
Bioorganic & Medicinal Chemistry Letters|March 16, 2013
N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: strategies to eliminate reactive metabolitesSajiv K Nair, Jean J Matthews, Stephan J Cripps, et al.
Bioorganic & Medicinal Chemistry Letters|June 4, 2011
Structure-based design of thienobenzoxepin inhibitors of PI3-kinaseSteven T Staben, Michael Siu, Richard Goldsmith, et al.
Journal of Medicinal Chemistry|October 30, 2025
Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory DiseasesSnahel Patel, Huifen Chen, Eugene Varfolomeev, et al.
Pageof 36